SERA
$1.83+0.05 (+2.51%)
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
Recent News
Sera Prognostics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Sera Prognostics, Inc.'s Q4 2025 earnings call
Sera Prognostics Inc (SERA) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...
Sera Prognostics Inc (SERA) reports a mixed quarter with declining revenue but strategic advancements in state engagement and European market entry.
Sera Prognostics Q4 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) executives emphasized progress in evidence generation and early commercialization efforts during the company’s fourth-quarter and full-year 2025 earnings call, held March 18, 2026. Management highlighted the publication of its pivotal PRIME study, a growing pipeline of
Sera Prognostics Q4 2025 Earnings Call Transcript
As we shared last year, to support Sera Prognostics, Inc.'s next phase of commercialization, we strengthened our leadership team with Lee Anderson joining us as Chief Commercial Officer and Doctor Tiffany Inglis as our Chief Medical Officer, enhancing our commercial and clinical depth, and I wanted to use this opportunity to introduce them to all of you in today's call and have them discuss our progress with you. was a critical year for Sera Prognostics, Inc. finalizing our PRIME publication to advance our evidence portfolio, setting up for commercial push in 2026, building our organization, ensuring we have capital to deploy in our commercialization efforts, and laying groundwork for potent...
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
Sera Prognostics (SERA) delivered earnings and revenue surprises of +5.88% and -75.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?